title: Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.
abstract: Particulate delivery systems enhance antibody responses to subunit antigens. However, covalent attachment of protein antigens can disrupt protein structure and mask critical epitopes, altering the antibody response to the antigen. In this report, we evaluate noncovalent metal chelation via nitrilotriacetic acid (NTA) as a nondestructive method to attach peptide and protein antigens to liposomes. Two model antigens, ovalbumin (OVA) and a peptide derived from the membrane-proximal region of HIV-1 gp41 (N-MPR), were polyhistidinylated and attached to liposomes via monovalent NTA (mono-NTA; K(D) [equilibrium dissociation constant], ∼10 μM), trivalent NTA (tris-NTA; K(D), ∼1 nM), or a covalent linkage. Attachment of N-MPR, but not OVA, to liposomes via an NTA lipid elicited stronger antibody responses in BALB/c mice than a formulation in which unassociated antigen was simply admixed with control liposomes lacking NTA. However, the tris-NTA linkage did not increase antibody responses to either N-MPR or OVA compared to the level for the mono-NTA linkage, despite the greater liposomal association of the antigen. For both antigens, covalently attaching them to a lipid elicited significantly stronger antibody responses than NTA-anchored antigens (OVA titer, 3.4 × 10(6) versus 1.4 × 10(6) to 1.6 × 10(6) [P < 0.001]; N-MPR titer, 4.4 × 10(4) versus 5.5 × 10(2) to 7.6 × 10(2) [P < 0.003]). The data indicate that NTA linkages may increase antibody titers to weak antigens such as N-MPR, but NTA-mediated attachment remains inferior to covalent conjugation. Moreover, enhancements in antigen-liposome affinity do not result in increased antibody titers. Thus, additional improvements of NTA-mediated conjugation technology are necessary to achieve an effective, nondestructive method for increasing the humoral response to antigens in particulate vaccines.
authors.affiliation: Department of Bioengineering, School of Pharmacy, University of California, San Francisco, CA 94143-0912, USA. szoka@cgl.ucsf.edu
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Watson
authors.forename: Virginia M
authors.initials: VM
authors.lastname: Platt
authors.forename: Limin
authors.initials: L
authors.lastname: Cao
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Venditto
authors.forename: Francis C
authors.initials: FC
authors.lastname: Szoka
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000097:blood*; D000941:Antigens / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D006639:Histidine / Q000737:chemistry / Q000378:metabolism*; D008081:Liposomes / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009571:Nitrilotriacetic Acid / Q000737:chemistry / Q000378:metabolism*; D010047:Ovalbumin / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D011485:Protein Binding; D022223:Vaccines, Subunit / Q000737:chemistry / Q000276:immunology / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D000941:Antigens; D015700:HIV Envelope Protein gp41; D008081:Liposomes; D010455:Peptides; D022223:Vaccines, Subunit; C514787:gp41 protein, Human immunodeficiency virus 1; C033223:polyhistidine; D006639:Histidine; D010047:Ovalbumin; D009571:Nitrilotriacetic Acid